RE: RE: RVX on Forbes .... further to chesterhalifax's comments, Ialso find the timing of this article interesting as John LaMattina, in addition to his role with Torcetrapib, also would have been a key decision maker at Pfizer during the time they purchased Esperion. That purchase was a complete disaster for Phizer while at the same time enriching Jan Johannson of Resverlogix. Perhaps someone is still chewing on some sour grapes? While I would be the first to agree that RVX has not crossed the finish line yet I think the article did not do anything to distinguish between RVX-208 and CETP inhibitors and between the lines one might infer from the article that big pharma CETP inhibitors are ahead of RVX simply because more money is being thown at them. In any event, time will tell however I would hope that current Pharma executives would not be taking to much advice from a person who would have been key in two huge failures for Pfizer and in general was part of the leadership that took Pfizer from a $45 stock to a close to $20 stock (split corrected).